Business Context and Reporting Period
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer and other breast conditions. Its lead candidate is oral (Z)-endoxifen, being developed for breast cancer treatment, prevention, and reduction of mammographic breast density. The company is not currently marketing products and generated no revenue in the quarter.
This unaudited Form 10-Q covers the three months ended March 31, 2024, with comparative results for the three months ended March 31, 2023. The filing was signed on May 13, 2024.
Financial Position and Results
| Metric | Q1 2024 | Q1 2023 or comparable balance | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $3.748 million | $3.508 million | Up $0.240 million |
| General and administrative expense | $3.232 million | $3.590 million | Down $0.358 million |
| Total operating expenses | $6.980 million | $7.098 million | Down $0.118 million |
| Operating loss | $6.980 million | $7.098 million | Improved $0.118 million |
| Interest income | $1.138 million | $0.850 million | Up $0.288 million |
| Net loss | $5.878 million | $6.281 million | Improved $0.403 million |
| Basic and diluted loss per share | $0.05 loss | $0.05 loss | Reported amount unchanged |
| Net cash used in operating activities | $4.698 million | $7.022 million | Use decreased $2.324 million |
Margins are not meaningful because the company has no revenue. The company has incurred losses and negative operating cash flows since inception.
| Balance sheet item | March 31, 2024 | December 31, 2023 |
|---|---|---|
| Cash and cash equivalents | $83.960 million | $88.460 million |
| Cash, cash equivalents and restricted cash | $84.070 million | $88.570 million |
| Working capital | $81.7 million | Not clearly provided in the filing text |
| Total assets | $91.087 million | $96.252 million |
| Total liabilities | $5.328 million | $5.236 million |
| Stockholders’ equity | $85.759 million | $91.016 million |
| Accumulated deficit | $192.166 million | $186.288 million |
The filing does not report outstanding debt; total liabilities consist of current liabilities. Cash declined by $4.5 million during the quarter, including $4.7 million of operating cash use, $6 thousand of capital expenditures, and $0.2 million of proceeds from warrant exercises.
Material Changes Versus the Prior Comparable Period
- R&D expense increased primarily because clinical and non-clinical trial spending for (Z)-endoxifen increased by $0.548 million.
- R&D compensation expense declined by $0.408 million, primarily due to lower non-cash stock-based compensation.
- G&A expense declined by $0.358 million, primarily because compensation expense decreased by $0.759 million.
- G&A professional fees increased by $0.516 million, primarily due to higher patent-related legal activity.
- Interest income increased by $0.288 million due to a higher-yielding mix of money market accounts.
- Net loss improved by $0.403 million, and operating cash use improved by $2.324 million, versus Q1 2023.
- The company issued 203,750 common shares upon warrant exercises for approximately $0.2 million of proceeds. No shares were repurchased during the quarter.
- Stock-based compensation declined to $0.417 million from $1.573 million in the prior-year quarter.
Outlook, Commentary, Risks, and Unusual Items
- Management believes available cash and cash equivalents are sufficient to fund operations for at least one year from the date the financial statements were issued. The company expects continuing operating losses and states that substantial additional capital will be required over the next several years.
- Potential funding sources include public or private equity, debt financing, collaborations, licenses, and other arrangements. Financing may be unavailable or unfavorable; insufficient funding could require the company to delay, modify, curtail, or suspend operations.
- The Karisma-(Z)-endoxifen Phase 2 study in mammographic breast density fully enrolled in November 2023, with primary data expected in the second half of 2024.
- Enrollment in the Phase 2 I-SPY clinical trial arm was completed in January 2024. On April 15, 2024, the company announced a new study of (Z)-endoxifen combined with abemaciclib, expected to enroll approximately 20 women.
- The company has no current product revenue and does not expect revenue unless and until pharmaceutical programs are successfully developed and launched. No quantitative financial guidance was provided.
- The company recorded a $1.8 million current liability related to uncertainty over the sustainability of its Australian R&D tax position under audit. Additional changes in estimate, penalties, or loss of expected rebates remain possible.
- Intas Pharmaceuticals filed a post-grant review petition seeking to invalidate a U.S. patent covering methods for making and using endoxifen. The company is contesting the petition, but cannot assure a favorable outcome.
- Estimated non-cancellable clinical-trial commitments were $5.7 million as of March 31, 2024, expected to be paid over trials anticipated to be completed in 2025.
- The company had $8.5 million remaining under its $10.0 million share repurchase authorization as of March 31, 2024; no repurchases occurred in the quarter.
- As of March 31, 2024, outstanding warrants represented 21.3 million potential shares, and options represented 17.4 million potential shares. These securities were excluded from diluted loss per share because they were anti-dilutive.
- The company regained compliance with Nasdaq’s minimum $1.00 closing bid-price requirement on March 15, 2024, but continued listing remains a risk.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2024, and reported no material changes in internal control over financial reporting.
Investor Verification Priorities
- Verify the timing, enrollment, safety, and efficacy data from the Karisma, EVANGELINE, RECAST, I-SPY, and abemaciclib-combination programs.
- Assess the company’s cash runway against the stated $4.7 million quarterly operating cash burn and planned clinical-trial spending.
- Monitor the need, timing, terms, and potential dilution of future capital raises, particularly given the company’s lack of revenue.
- Track the Intas post-grant review and the Indian patent opposition, including any effect on (Z)-endoxifen intellectual-property protection.
- Verify the outcome of any Australian Taxation Office review and whether the $1.8 million accrued liability adequately reflects potential exposure.
- Evaluate the dilution and cash proceeds associated with outstanding warrants, stock options, and convertible preferred stock.
- Monitor Nasdaq listing compliance and the company’s ability to maintain sufficient authorized shares for financing or other corporate purposes.